Loading
Nanoparticle-based Drug Delivery / RNA Interference and Gene Delivery · Journal article
Current Pharmaceutical Design · July 22, 2026
Raises a question worth testing. It does not answer one.
This is a comprehensive narrative review of lipid-based nanocarriers (liposomes, SLNs, NLCs, transferosomes, ethosomes, invasomes) for skin cancer therapy. It synthesizes preclinical mechanisms, physicochemical properties, targeting strategies, and early translational work—including mRNA vaccines—but reports no original clinical trial data or comparative efficacy results. The review identifies lipid nanocarriers as a promising platform concept rather than establishing clinical practice-relevant evidence.
Narrative review. Patients with skin cancer (melanoma and non-melanoma subtypes).
LBNCs overcome stratum corneum barrier through hydration, lipid fluidization, and follicular targeting mechanisms Lipid nanoparticles function as nonviral vectors for siRNA, mRNA, and CRISPR/Cas9 delivery to modulate oncogenic pathways Personalized mRNA-based cancer vaccines represent recent preclinical and early clinical development
Conventional treatments (surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy) are limited by poor cutaneous penetration, systemic toxicity, non-specific distribution, and drug resistance
This review synthesizes therapeutic concepts and mechanisms but does not provide clinical trial evidence to guide current practice. Clinicians should view lipid nanocarriers as an emerging research direction rather than an established treatment modality pending confirmatory clinical data.
This is a narrative review summarizing preclinical mechanisms and early translational potential of lipid nanocarriers for skin cancer, raising questions rather than answering them with clinical evidence.
As stated by the source record.
This review synthesizes therapeutic concepts and mechanisms but does not provide clinical trial evidence to guide current practice. Clinicians should view lipid nanocarriers as an emerging research direction rather than an established treatment modality pending confirmatory clinical data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Skin cancer, including melanoma and non-melanoma subtypes, remains a major global health challenge with steadily rising incidence rates. Although conventional treatment modalities such as surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy have improved patient outcomes, their clinical effectiveness is frequently limited by poor cutaneous penetration, systemic toxicity, non-specific drug distribution, and the emergence of drug resistance. In this context, lipid-based nanocarriers (LBNCs) have emerged as a promising strategy to address these therapeutic limitations. This comprehensive review highlights recent advances in LBNCs, including liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), transferosomes, ethosomes, and invasomes, for the management of skin cancer. The review discusses the physicochemical properties and mechanisms by which these nanocarriers enhance topical and transdermal drug delivery by overcoming the stratum corneum barrier through hydration, lipid fluidization, and follicular targeting. Furthermore, the role of LBNCs in achieving tumor-specific accumulation via passive targeting through the enhanced permeability and retention (EPR) effect, as well as active targeting using ligandfunctionalized systems, is critically examined. Particular emphasis is placed on lipid nanoparticles as nonviral vectors for gene therapy, enabling the efficient delivery of nucleic acids such as siRNA, mRNA, and CRISPR/Cas9 components to modulate oncogenic pathways. Recent preclinical and clinical developments, including personalized mRNA-based cancer vaccines, are summarized to demonstrate the translational potential of LBNCs. Overall, this review underscores the versatility of lipid-based nanocarriers as multifunctional, biocompatible, and patient-friendly platforms, offering new opportunities for precise, effective, and personalized skin cancer therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.